Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1) / G. PINI in Autism Research and Treatment, 2016 (2016)  

Public ISBD [article]  inAutism Research and Treatment > 2016 (2016) Titre : Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1) Type de document : Texte imprimé et/ou numérique Auteurs : G. PINI, Auteur ; L. CONGIU, Auteur ; Alberto BENINCASA, Auteur ; P. DIMARCO, Auteur ; S. BIGONI, Auteur ; A. H. DYER, Auteur ; N. MORTIMER, Auteur ; A. DELLA-CHIESA, Auteur ; S. O'LEARY, Auteur ; R. MCNAMARA, Auteur ; K. J. MITCHELL, Auteur ; M. GILL, Auteur ; D. TROPEA, Auteur Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Rett Syndrome (RTT) is a severe neurodevelopmental disorder characterized by an apparently normal development followed by an arrest and subsequent regression of cognitive and psychomotor abilities. At present, RTT has no definitive cure and the treatment of RTT represents a largely unmet clinical need. Following partial elucidation of the underlying neurobiology of RTT, a new treatment has been proposed, Mecasermin (recombinant human Insulin-Like Growth Factor 1), which, in addition to impressive evidence from preclinical murine models of RTT, has demonstrated safety in human studies of patients with RTT. The present clinical study examines the disease severity as assessed by clinicians (International Scoring System: ISS), social and cognitive ability assessed by two blinded, independent observers (RSS: Rett Severity Score), and changes in brain activity (EEG) parameters of ten patients with classic RTT and ten untreated patients matched for age and clinical severity. Significant improvement in both the ISS (p = 0.0106) and RSS (p = 0.0274) was found in patients treated with IGF1 in comparison to untreated patients. Analysis of the novel RSS also suggests that patients treated with IGF1 have a greater endurance to social and cognitive testing. The present clinical study adds significant preliminary evidence for the use of IGF-1 in the treatment of RTT and other disorders of the autism spectrum. En ligne : http://dx.doi.org/10.1155/2016/5073078 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=332 [article] Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1) [Texte imprimé et/ou numérique] / G. PINI, Auteur ; L. CONGIU, Auteur ; Alberto BENINCASA, Auteur ; P. DIMARCO, Auteur ; S. BIGONI, Auteur ; A. H. DYER, Auteur ; N. MORTIMER, Auteur ; A. DELLA-CHIESA, Auteur ; S. O'LEARY, Auteur ; R. MCNAMARA, Auteur ; K. J. MITCHELL, Auteur ; M. GILL, Auteur ; D. TROPEA, Auteur. Langues : Anglais (eng) in Autism Research and Treatment > 2016 (2016) Index. décimale : PER Périodiques Résumé : Rett Syndrome (RTT) is a severe neurodevelopmental disorder characterized by an apparently normal development followed by an arrest and subsequent regression of cognitive and psychomotor abilities. At present, RTT has no definitive cure and the treatment of RTT represents a largely unmet clinical need. Following partial elucidation of the underlying neurobiology of RTT, a new treatment has been proposed, Mecasermin (recombinant human Insulin-Like Growth Factor 1), which, in addition to impressive evidence from preclinical murine models of RTT, has demonstrated safety in human studies of patients with RTT. The present clinical study examines the disease severity as assessed by clinicians (International Scoring System: ISS), social and cognitive ability assessed by two blinded, independent observers (RSS: Rett Severity Score), and changes in brain activity (EEG) parameters of ten patients with classic RTT and ten untreated patients matched for age and clinical severity. Significant improvement in both the ISS (p = 0.0106) and RSS (p = 0.0274) was found in patients treated with IGF1 in comparison to untreated patients. Analysis of the novel RSS also suggests that patients treated with IGF1 have a greater endurance to social and cognitive testing. The present clinical study adds significant preliminary evidence for the use of IGF-1 in the treatment of RTT and other disorders of the autism spectrum. En ligne : http://dx.doi.org/10.1155/2016/5073078 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=332

Training the social brain: Clinical and neural effects of an 8-week real-time functional magnetic resonance imaging neurofeedback Phase IIa Clinical Trial in Autism / B. DIREITO in Autism, 25-6 (August 2021)  

Public ISBD [article]  inAutism > 25-6 (August 2021) . - p.1746-1760 Titre : Training the social brain: Clinical and neural effects of an 8-week real-time functional magnetic resonance imaging neurofeedback Phase IIa Clinical Trial in Autism Type de document : Texte imprimé et/ou numérique Auteurs : B. DIREITO, Auteur ; S. MOUGA, Auteur ; A. SAYAL, Auteur ; M. SIMÕES, Auteur ; H. QUENTAL, Auteur ; I. BERNARDINO, Auteur ; R. PLAYLE, Auteur ; R. MCNAMARA, Auteur ; D. E. LINDEN, Auteur ; G. OLIVEIRA, Auteur ; Miguel CASTELO-BRANCO, Auteur Article en page(s) : p.1746-1760 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnostic imaging/therapy  Autistic Disorder/diagnostic imaging/therapy  Brain/diagnostic imaging  Humans  Magnetic Resonance Imaging  Neurofeedback  autism spectrum disorder  neurorehabilitation  posterior superior temporal sulcus  real-time functional magnetic resonance imaging  social cognition Index. décimale : PER Périodiques Résumé : Neurofeedback is an emerging therapeutic approach in neuropsychiatric disorders. Its potential application in autism spectrum disorder remains to be tested. Here, we demonstrate the feasibility of real-time functional magnetic resonance imaging volitional neurofeedback in targeting social brain regions in autism spectrum disorder. In this clinical trial, autism spectrum disorder patients were enrolled in a program with five training sessions of neurofeedback. Participants were able to control their own brain activity in this social brain region, with positive clinical and neural effects. Larger, controlled, and blinded clinical studies will be required to confirm the benefits. En ligne : http://dx.doi.org/10.1177/13623613211002052 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=451 [article] Training the social brain: Clinical and neural effects of an 8-week real-time functional magnetic resonance imaging neurofeedback Phase IIa Clinical Trial in Autism [Texte imprimé et/ou numérique] / B. DIREITO, Auteur ; S. MOUGA, Auteur ; A. SAYAL, Auteur ; M. SIMÕES, Auteur ; H. QUENTAL, Auteur ; I. BERNARDINO, Auteur ; R. PLAYLE, Auteur ; R. MCNAMARA, Auteur ; D. E. LINDEN, Auteur ; G. OLIVEIRA, Auteur ; Miguel CASTELO-BRANCO, Auteur . - p.1746-1760. Langues : Anglais (eng) in Autism > 25-6 (August 2021) . - p.1746-1760 Mots-clés : Autism Spectrum Disorder/diagnostic imaging/therapy  Autistic Disorder/diagnostic imaging/therapy  Brain/diagnostic imaging  Humans  Magnetic Resonance Imaging  Neurofeedback  autism spectrum disorder  neurorehabilitation  posterior superior temporal sulcus  real-time functional magnetic resonance imaging  social cognition Index. décimale : PER Périodiques Résumé : Neurofeedback is an emerging therapeutic approach in neuropsychiatric disorders. Its potential application in autism spectrum disorder remains to be tested. Here, we demonstrate the feasibility of real-time functional magnetic resonance imaging volitional neurofeedback in targeting social brain regions in autism spectrum disorder. In this clinical trial, autism spectrum disorder patients were enrolled in a program with five training sessions of neurofeedback. Participants were able to control their own brain activity in this social brain region, with positive clinical and neural effects. Larger, controlled, and blinded clinical studies will be required to confirm the benefits. En ligne : http://dx.doi.org/10.1177/13623613211002052 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=451

---

1 (1 - 2 / 2)